| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/23/2013 | WO2011119047A8 Carvacrol/thymol composition for the treatment of salmonid rickettsial septicemia and infectious salmon anemia |
| 05/23/2013 | US20130133092 Sequence-specific dna recombination in eukaryotic cells |
| 05/23/2013 | US20130131621 Dressing device |
| 05/23/2013 | US20130131429 Methods and systems for treating cell proliferation disorders with psoralen derivatives |
| 05/23/2013 | US20130131338 Substituted diketopiperazines as oxytocin antagonists |
| 05/23/2013 | US20130131317 Expression of secreted human alpha-fetoprotein in transgenic animals |
| 05/23/2013 | US20130131191 Additive for tablets |
| 05/23/2013 | US20130131186 Microemulsion Preparation of High Concentration Propofol for Anesthetic Uses |
| 05/23/2013 | US20130131183 Methods and compositions for improving the health of animals |
| 05/23/2013 | US20130131181 Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas |
| 05/23/2013 | US20130131179 Iron metabolism-improving agent |
| 05/23/2013 | US20130131178 Use of oxaloacetate in the treatment of ischaemia |
| 05/23/2013 | US20130131177 Use of a dermatological composition comprising a combination of adapalene and benzoyl peroxide which is intended for the treatment of acne in non-caucasian population with decrease of post-inflammatory hyperpigmentation |
| 05/23/2013 | US20130131176 High Concentration Baclofen Preparations |
| 05/23/2013 | US20130131175 Creatine oral supplementation using creatine hydrochloride salt |
| 05/23/2013 | US20130131174 Injectable pharmaceutical formulation of melphalan |
| 05/23/2013 | US20130131171 Treatment for Meibomian Gland Dysfunction or Obstruction |
| 05/23/2013 | US20130131170 Methods of treating hypertriglyceridemia |
| 05/23/2013 | US20130131162 Vitamin C Composition for Use in the Prevention and Treatment of Stretch Marks, Radiation Dermatitis, and Other Skin Conditions and Methods of Using the Same |
| 05/23/2013 | US20130131161 Methods and compositions for cardiovascular diseases and conditions |
| 05/23/2013 | US20130131160 New use of hesperetin |
| 05/23/2013 | US20130131159 Plectranthus amboinicus fraction having anti-arthritis activity |
| 05/23/2013 | US20130131158 Antiviral composition |
| 05/23/2013 | US20130131155 Optimized In Vivo Delivery System with Endosomolytic Agents for Nucleic Acid Conjugates |
| 05/23/2013 | US20130131152 Hypoxia regulated conditionally silenced aav expressing angiogenic inducers |
| 05/23/2013 | US20130131151 Method for photopolymerizing hydrogel using x-ray irradiation |
| 05/23/2013 | US20130131148 Micro-rna for cancer diagnosis, prognosis and therapy |
| 05/23/2013 | US20130131146 Compositions and Methods for Treating Pulmonary Conditions |
| 05/23/2013 | US20130131139 Ror1 as a gene target in acute lymphoblastic leukemia |
| 05/23/2013 | US20130131138 NOVEL FORMS OF [R-(R*,R*)]-2-(4-FLUOROPHENYL)-b,d-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID MAGNESIUM |
| 05/23/2013 | US20130131133 Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases |
| 05/23/2013 | US20130131131 Bendamustine Pharmaceutical Compositions |
| 05/23/2013 | US20130131129 Reversing Intestinal Inflammation by Inhibiting Retinoic Acid Metabolism |
| 05/23/2013 | US20130131128 Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof |
| 05/23/2013 | US20130131127 Method of using dopamine reuptake inhibitors and their analogs for treating diabetes symptoms and delaying or preventing diabetes-associated pathologic conditions |
| 05/23/2013 | US20130131125 Therapeutic combination |
| 05/23/2013 | US20130131123 Oral Dosage Form Containing A Pde 4 Inhibitor As An Active Ingredient And Polyvinylpyrrolidon As Excipient |
| 05/23/2013 | US20130131122 Fluro substituted Omega-Carboxyaryl Diphenyl Urea for the Treatment and Prevention of Diseases and Conditions |
| 05/23/2013 | US20130131121 Anti-viral agent |
| 05/23/2013 | US20130131120 Therapeutic agent or prophylactic agent for neuropathic pain |
| 05/23/2013 | US20130131113 Pyridone glucokinase activators |
| 05/23/2013 | US20130131111 Nmn modulators for the treatment of neurodegenerative disorders |
| 05/23/2013 | US20130131110 Compositions for the Treatment of CNS-Related Conditions |
| 05/23/2013 | US20130131108 Methods of treating obstructive lung diseases using bitter tastants |
| 05/23/2013 | US20130131107 Pharmaceutical compositions and administrations thereof |
| 05/23/2013 | US20130131103 Methods and Compositions For Improved Nerve Conduction Velocity |
| 05/23/2013 | US20130131101 Tetrahydropyridoethers for treatment of amd |
| 05/23/2013 | US20130131098 Pharmaceutical formulation of apomorphine for buccal administration |
| 05/23/2013 | US20130131097 Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide f2 alpha agonists |
| 05/23/2013 | US20130131094 Pyrimidine derivatives as posh and posh-ap inhibitors |
| 05/23/2013 | US20130131088 Treating cancer with statins and compounds having dipyridamole activity |
| 05/23/2013 | US20130131087 Pharmaceutical Compositions |
| 05/23/2013 | US20130131081 Pharmaceutical compositions including carbamoyloxy arylalkanoyl arylpiperazine compound |
| 05/23/2013 | US20130131079 Flufenoxine derivatives for the treatment and prevention of amyloid pathologies |
| 05/23/2013 | US20130131076 Methods and compositions related to wrapping of dehydrons |
| 05/23/2013 | US20130131074 Pyridone and pyridazone analogues as gpr119 modulators |
| 05/23/2013 | US20130131073 Fused-imidazoyl compounds useful as antimicrobial agents |
| 05/23/2013 | US20130131072 Methods for Optimizing Clinical Responsiveness to Methotrexate Therapy Using Metabolite Profiling and Pharmacogenetics |
| 05/23/2013 | US20130131071 Use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species |
| 05/23/2013 | US20130131069 Method for treatment of solid malignancies including advanced or metastatic solid malignancies |
| 05/23/2013 | US20130131068 Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof |
| 05/23/2013 | US20130131066 Treatment of type 1 diabetes |
| 05/23/2013 | US20130131065 Treatment of type 2 diabetes |
| 05/23/2013 | US20130131063 Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners |
| 05/23/2013 | US20130131060 3-(indolyl)- or 3-(azaindolyl)- 4-arylmaleimide compounds and their use in tumor treatment |
| 05/23/2013 | US20130131057 New bicyclic compounds as pi3-k and mtor inhibitors |
| 05/23/2013 | US20130131055 Furopyridinyl-substituted 1,4-dihydropyridine derivatives and methods of use thereof |
| 05/23/2013 | US20130131054 Tetracyclic compounds |
| 05/23/2013 | US20130131052 Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases |
| 05/23/2013 | US20130131050 Fused heterocyclic compound and application thereof |
| 05/23/2013 | US20130131046 Noribogaine compositions |
| 05/23/2013 | US20130131038 N-containing heteroaryl derivatives as jak3 kinase inhibitors |
| 05/23/2013 | US20130131037 2-(heterocyclylbenzyl)pyridazinone derivatives |
| 05/23/2013 | US20130131036 Novel trpv3 modulators |
| 05/23/2013 | US20130131033 Pharmaceutical composition for treatment of respiratory tract infections |
| 05/23/2013 | US20130131032 Neurotherapeutic treatment for sexual dysfunction |
| 05/23/2013 | US20130131031 Method of treating refractory cancer |
| 05/23/2013 | US20130131030 Optimizing mifepristone absorption |
| 05/23/2013 | US20130131028 Methods for treatment of sleep-related breathing disorders |
| 05/23/2013 | US20130131027 Parenteral pharmaceutical form which releases aromatse inhibitor and gestagens, for the treatment of endometriosis |
| 05/23/2013 | US20130131026 Compositions and methods for treating symptoms of inflammatory related conditions using a combination of an antihistamine and a stimulant |
| 05/23/2013 | US20130131025 Hyperlipemia-ameliorating agent, anemia-ameliorating composition, uric-acid-level-reducing composition, and food or beverage |
| 05/23/2013 | US20130131024 Methods and compositions for the treatment of fluid accumulation in and/ or under the retina |
| 05/23/2013 | US20130131023 New polymorphic form of a calcimimetic compound |
| 05/23/2013 | US20130131022 Methods for Controlled Release Oral Dosage of a Vitamin D Compound |
| 05/23/2013 | US20130131021 Analogues of cilostazol |
| 05/23/2013 | US20130131018 Substituted isoquinolines and their use as tubulin polymerization inhibitors |
| 05/23/2013 | US20130131017 Boron-containing small molecules |
| 05/23/2013 | US20130131014 Prevention and treatment of secondary infections following viral infection |
| 05/23/2013 | US20130131013 Cyclodextrin-based polymers for therapeutics delivery |
| 05/23/2013 | US20130131011 Hyaluronic acid-based gels including lidocaine |
| 05/23/2013 | US20130131010 Galactose-pronged polysaccharides in a formulation for antifibrotic therapies |
| 05/23/2013 | US20130131007 Vitamin b12 compositions |
| 05/23/2013 | US20130131006 Method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of age-albumin in cells of the mononuclear phagocyte system |
| 05/23/2013 | US20130131005 Methods and compositions for providing cardiac protection |
| 05/23/2013 | US20130131004 Proliferation inhibitor of helicobacter pylori bacteria |
| 05/23/2013 | US20130131002 Compositions and methods for treating pulmonary hypertension |
| 05/23/2013 | US20130131000 Composition Comprising Ligustroflavone, Rhoifolin and Hyperin and Its Pharmaceutical Application |
| 05/23/2013 | US20130130999 Method of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors |
| 05/23/2013 | US20130130998 Analogues of Etoposide for the Treatment of Tumours |